Mid-IR Photonic Biosensor for Point-of-Care Molecular Diagnostics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Molecular diagnostics for diseases often require complex processes and centralized laboratories, leading to high costs and delays in obtaining results, as existing techniques like PCR are not suitable for point-of-care testing.
Innovation Solution
A photonic biosensing platform using mid-IR absorption spectroscopy with waveguide-based sensors, integrated into chip-scale platforms, that enables detection of biological analytes by measuring specific absorptions, potentially eliminating the need for amplification steps like PCR and allowing diagnostics at the point of care.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PCR and fluorescence spectroscopy are used for molecular diagnostics, then detection sensitivity is improved, but device complexity and cost increase
Solution Approach 1:
The patent extracts the core detection function from the complex PCR system by using mid-IR absorption spectroscopy to directly detect biological markers without requiring amplification steps. This removes the need for complex thermal cycling equipment and reagents while maintaining detection capability through the characteristic absorption signatures of biomolecules in the mid-IR region.
Solution Approach 2:
The patent replaces the mechanical and chemical amplification processes of PCR with an optical detection method. Instead of using thermal cycling and enzymatic amplification, the system uses mid-IR light absorption to directly detect and quantify biological markers, substituting a simpler optical measurement for complex biochemical processes.
2Measurement precision
If centralized laboratory testing is used, then measurement precision is improved, but time to obtain results increases
Solution Approach 1:
The patent enables point-of-care testing by making the diagnostic system self-sufficient without requiring centralized laboratory infrastructure. The integrated mid-IR sensor platform can perform detection locally at the patient site, eliminating the need to transport samples to centralized facilities and providing results immediately without centralized processing delays.
3Ease of operation
If point-of-care testing is implemented, then ease of operation is improved, but measurement precision deteriorates
Solution Approach 1:
The patent changes the detection parameter from requiring amplified signals (as in PCR) to detecting intrinsic mid-IR absorption properties of biomolecules. This parameter change allows direct detection without amplification, maintaining sufficient sensitivity for point-of-care use while enabling portable, simple operation. The characteristic absorption bands of biological markers in the mid-IR region provide unique fingerprints that can be detected with high specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables high-sensitivity detection of biological targets directly at the point of care, reducing costs and time to results, and facilitating the integration of molecular diagnostics into smaller, more affordable systems.
Implementation Method 1
photonic biosensing platform using mid-IR absorption spectroscopy
Data Source
AI summary
A photonic biosensor including a biological probe disposed on a mid-infrared-transparent waveguide can be used to detect biological analytes in biological samples, using specific binding of the analyte to the probe in conjunction with absorption spectroscopy. In various embodiments, the biosensor is used for molecular diagnostics, e.g., to detect oligonucleotides or proteins associated with a coronavirus.